List of Tables
Table 1. Global Osteoporosis Biosimilars Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Osteoporosis Biosimilars Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Osteoporosis Biosimilars Market Competitive Situation by Manufacturers in 2024
Table 4. Global Osteoporosis Biosimilars Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Osteoporosis Biosimilars Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Osteoporosis Biosimilars Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Osteoporosis Biosimilars Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Osteoporosis Biosimilars Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Osteoporosis Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Osteoporosis Biosimilars, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Osteoporosis Biosimilars, Product Type & Application
Table 12. Global Key Manufacturers of Osteoporosis Biosimilars, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Osteoporosis Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Osteoporosis Biosimilars as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Osteoporosis Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Osteoporosis Biosimilars Sales by Region (2020-2025) & (K Units)
Table 18. Global Osteoporosis Biosimilars Sales Market Share by Region (2020-2025)
Table 19. Global Osteoporosis Biosimilars Sales by Region (2026-2031) & (K Units)
Table 20. Global Osteoporosis Biosimilars Sales Market Share by Region (2026-2031)
Table 21. Global Osteoporosis Biosimilars Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Osteoporosis Biosimilars Revenue Market Share by Region (2020-2025)
Table 23. Global Osteoporosis Biosimilars Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Osteoporosis Biosimilars Revenue Market Share by Region (2026-2031)
Table 25. North America Osteoporosis Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Osteoporosis Biosimilars Sales by Country (2020-2025) & (K Units)
Table 27. North America Osteoporosis Biosimilars Sales by Country (2026-2031) & (K Units)
Table 28. North America Osteoporosis Biosimilars Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Osteoporosis Biosimilars Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Osteoporosis Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Osteoporosis Biosimilars Sales by Country (2020-2025) & (K Units)
Table 32. Europe Osteoporosis Biosimilars Sales by Country (2026-2031) & (K Units)
Table 33. Europe Osteoporosis Biosimilars Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Osteoporosis Biosimilars Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Osteoporosis Biosimilars Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Osteoporosis Biosimilars Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Osteoporosis Biosimilars Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Osteoporosis Biosimilars Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Osteoporosis Biosimilars Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Osteoporosis Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Osteoporosis Biosimilars Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Osteoporosis Biosimilars Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Osteoporosis Biosimilars Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Osteoporosis Biosimilars Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Osteoporosis Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Osteoporosis Biosimilars Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Osteoporosis Biosimilars Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Osteoporosis Biosimilars Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Osteoporosis Biosimilars Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Osteoporosis Biosimilars Sales (K Units) by Type (2020-2025)
Table 51. Global Osteoporosis Biosimilars Sales (K Units) by Type (2026-2031)
Table 52. Global Osteoporosis Biosimilars Sales Market Share by Type (2020-2025)
Table 53. Global Osteoporosis Biosimilars Sales Market Share by Type (2026-2031)
Table 54. Global Osteoporosis Biosimilars Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Osteoporosis Biosimilars Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Osteoporosis Biosimilars Revenue Market Share by Type (2020-2025)
Table 57. Global Osteoporosis Biosimilars Revenue Market Share by Type (2026-2031)
Table 58. Global Osteoporosis Biosimilars Price (US$/Unit) by Type (2020-2025)
Table 59. Global Osteoporosis Biosimilars Price (US$/Unit) by Type (2026-2031)
Table 60. Global Osteoporosis Biosimilars Sales (K Units) by Application (2020-2025)
Table 61. Global Osteoporosis Biosimilars Sales (K Units) by Application (2026-2031)
Table 62. Global Osteoporosis Biosimilars Sales Market Share by Application (2020-2025)
Table 63. Global Osteoporosis Biosimilars Sales Market Share by Application (2026-2031)
Table 64. Global Osteoporosis Biosimilars Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Osteoporosis Biosimilars Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Osteoporosis Biosimilars Revenue Market Share by Application (2020-2025)
Table 67. Global Osteoporosis Biosimilars Revenue Market Share by Application (2026-2031)
Table 68. Global Osteoporosis Biosimilars Price (US$/Unit) by Application (2020-2025)
Table 69. Global Osteoporosis Biosimilars Price (US$/Unit) by Application (2026-2031)
Table 70. Biosidus SA Company Information
Table 71. Biosidus SA Description and Business Overview
Table 72. Biosidus SA Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Biosidus SA Osteoporosis Biosimilars Product
Table 74. Biosidus SA Recent Developments/Updates
Table 75. Cadila Pharmaceuticals Company Information
Table 76. Cadila Pharmaceuticals Description and Business Overview
Table 77. Cadila Pharmaceuticals Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Cadila Pharmaceuticals Osteoporosis Biosimilars Product
Table 79. Cadila Pharmaceuticals Recent Developments/Updates
Table 80. Gedeon Richter Australia Pty Ltd Company Information
Table 81. Gedeon Richter Australia Pty Ltd Description and Business Overview
Table 82. Gedeon Richter Australia Pty Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Gedeon Richter Australia Pty Ltd Osteoporosis Biosimilars Product
Table 84. Gedeon Richter Australia Pty Ltd Recent Developments/Updates
Table 85. Mochida Pharmaceutical Co., Ltd Company Information
Table 86. Mochida Pharmaceutical Co., Ltd Description and Business Overview
Table 87. Mochida Pharmaceutical Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Mochida Pharmaceutical Co., Ltd Osteoporosis Biosimilars Product
Table 89. Mochida Pharmaceutical Co., Ltd Recent Developments/Updates
Table 90. STADA Arzneimittel AG Company Information
Table 91. STADA Arzneimittel AG Description and Business Overview
Table 92. STADA Arzneimittel AG Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. STADA Arzneimittel AG Osteoporosis Biosimilars Product
Table 94. STADA Arzneimittel AG Recent Developments/Updates
Table 95. Alvogen, Inc Company Information
Table 96. Alvogen, Inc Description and Business Overview
Table 97. Alvogen, Inc Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Alvogen, Inc Osteoporosis Biosimilars Product
Table 99. Alvogen, Inc Recent Developments/Updates
Table 100. Theramex Ireland Ltd Company Information
Table 101. Theramex Ireland Ltd Description and Business Overview
Table 102. Theramex Ireland Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Theramex Ireland Ltd Osteoporosis Biosimilars Product
Table 104. Theramex Ireland Ltd Recent Developments/Updates
Table 105. Intas Pharmaceuticals Ltd Company Information
Table 106. Intas Pharmaceuticals Ltd Description and Business Overview
Table 107. Intas Pharmaceuticals Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Intas Pharmaceuticals Ltd Osteoporosis Biosimilars Product
Table 109. Intas Pharmaceuticals Ltd Recent Developments/Updates
Table 110. Sun Pharma ANZ Pty Ltd Company Information
Table 111. Sun Pharma ANZ Pty Ltd Description and Business Overview
Table 112. Sun Pharma ANZ Pty Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Sun Pharma ANZ Pty Ltd Osteoporosis Biosimilars Product
Table 114. Sun Pharma ANZ Pty Ltd Recent Developments/Updates
Table 115. Strides Pharma Company Information
Table 116. Strides Pharma Description and Business Overview
Table 117. Strides Pharma Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Strides Pharma Osteoporosis Biosimilars Product
Table 119. Strides Pharma Recent Developments/Updates
Table 120. Apotex Corp Company Information
Table 121. Apotex Corp Description and Business Overview
Table 122. Apotex Corp Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Apotex Corp Osteoporosis Biosimilars Product
Table 124. Apotex Corp Recent Developments/Updates
Table 125. Teva Pharmaceuticals, Inc Company Information
Table 126. Teva Pharmaceuticals, Inc Description and Business Overview
Table 127. Teva Pharmaceuticals, Inc Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Teva Pharmaceuticals, Inc Osteoporosis Biosimilars Product
Table 129. Teva Pharmaceuticals, Inc Recent Developments/Updates
Table 130. Novartis AG Company Information
Table 131. Novartis AG Description and Business Overview
Table 132. Novartis AG Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Novartis AG Osteoporosis Biosimilars Product
Table 134. Novartis AG Recent Developments/Updates
Table 135. Cipla Ltd Company Information
Table 136. Cipla Ltd Description and Business Overview
Table 137. Cipla Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Cipla Ltd Osteoporosis Biosimilars Product
Table 139. Cipla Ltd Recent Developments/Updates
Table 140. CrownBio Science (Jilin) Co., Ltd Company Information
Table 141. CrownBio Science (Jilin) Co., Ltd Description and Business Overview
Table 142. CrownBio Science (Jilin) Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. CrownBio Science (Jilin) Co., Ltd Osteoporosis Biosimilars Product
Table 144. CrownBio Science (Jilin) Co., Ltd Recent Developments/Updates
Table 145. LianKang Biotechnology Group Company Information
Table 146. LianKang Biotechnology Group Description and Business Overview
Table 147. LianKang Biotechnology Group Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. LianKang Biotechnology Group Osteoporosis Biosimilars Product
Table 149. LianKang Biotechnology Group Recent Developments/Updates
Table 150. Shanghai United Cell Bioengineering Co., Ltd Company Information
Table 151. Shanghai United Cell Bioengineering Co., Ltd Description and Business Overview
Table 152. Shanghai United Cell Bioengineering Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Shanghai United Cell Bioengineering Co., Ltd Osteoporosis Biosimilars Product
Table 154. Shanghai United Cell Bioengineering Co., Ltd Recent Developments/Updates
Table 155. Shenzhen Salubris Pharmaceuticals Co., Ltd Company Information
Table 156. Shenzhen Salubris Pharmaceuticals Co., Ltd Description and Business Overview
Table 157. Shenzhen Salubris Pharmaceuticals Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. Shenzhen Salubris Pharmaceuticals Co., Ltd Osteoporosis Biosimilars Product
Table 159. Shenzhen Salubris Pharmaceuticals Co., Ltd Recent Developments/Updates
Table 160. Shandong Boyan Biotechnology Co., Ltd Company Information
Table 161. Shandong Boyan Biotechnology Co., Ltd Description and Business Overview
Table 162. Shandong Boyan Biotechnology Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Shandong Boyan Biotechnology Co., Ltd Osteoporosis Biosimilars Product
Table 164. Shandong Boyan Biotechnology Co., Ltd Recent Developments/Updates
Table 165. Mabwell (Shanghai) Biotechnology Company Information
Table 166. Mabwell (Shanghai) Biotechnology Description and Business Overview
Table 167. Mabwell (Shanghai) Biotechnology Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 168. Mabwell (Shanghai) Biotechnology Osteoporosis Biosimilars Product
Table 169. Mabwell (Shanghai) Biotechnology Recent Developments/Updates
Table 170. Qilu Pharmaceutical Co., Ltd Company Information
Table 171. Qilu Pharmaceutical Co., Ltd Description and Business Overview
Table 172. Qilu Pharmaceutical Co., Ltd Osteoporosis Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 173. Qilu Pharmaceutical Co., Ltd Osteoporosis Biosimilars Product
Table 174. Qilu Pharmaceutical Co., Ltd Recent Developments/Updates
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Osteoporosis Biosimilars Distributors List
Table 178. Osteoporosis Biosimilars Customers List
Table 179. Osteoporosis Biosimilars Market Trends
Table 180. Osteoporosis Biosimilars Market Drivers
Table 181. Osteoporosis Biosimilars Market Challenges
Table 182. Osteoporosis Biosimilars Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
Table 186. Authors List of This Report
List of Figures
Figure 1. Product Picture of Osteoporosis Biosimilars
Figure 2. Global Osteoporosis Biosimilars Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Osteoporosis Biosimilars Market Share by Type: 2024 & 2031
Figure 4. 250μg/mL Product Picture
Figure 5. 60 mg/mL Product Picture
Figure 6. 70 mg/mL Product Picture
Figure 7. Global Osteoporosis Biosimilars Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Osteoporosis Biosimilars Market Share by Application: 2024 & 2031
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Global Osteoporosis Biosimilars Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Osteoporosis Biosimilars Market Size (2020-2031) & (US$ Million)
Figure 14. Global Osteoporosis Biosimilars Sales (2020-2031) & (K Units)
Figure 15. Global Osteoporosis Biosimilars Average Price (US$/Unit) & (2020-2031)
Figure 16. Osteoporosis Biosimilars Report Years Considered
Figure 17. Osteoporosis Biosimilars Sales Share by Manufacturers in 2024
Figure 18. Global Osteoporosis Biosimilars Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Osteoporosis Biosimilars Players: Market Share by Revenue in Osteoporosis Biosimilars in 2024
Figure 20. Osteoporosis Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Osteoporosis Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Osteoporosis Biosimilars Sales Market Share by Country (2020-2031)
Figure 23. North America Osteoporosis Biosimilars Revenue Market Share by Country (2020-2031)
Figure 24. United States Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Osteoporosis Biosimilars Sales Market Share by Country (2020-2031)
Figure 27. Europe Osteoporosis Biosimilars Revenue Market Share by Country (2020-2031)
Figure 28. Germany Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Osteoporosis Biosimilars Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Osteoporosis Biosimilars Revenue Market Share by Region (2020-2031)
Figure 35. China Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Osteoporosis Biosimilars Sales Market Share by Country (2020-2031)
Figure 43. Latin America Osteoporosis Biosimilars Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Colombia Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Osteoporosis Biosimilars Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Osteoporosis Biosimilars Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Osteoporosis Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Osteoporosis Biosimilars by Type (2020-2031)
Figure 54. Global Revenue Market Share of Osteoporosis Biosimilars by Type (2020-2031)
Figure 55. Global Osteoporosis Biosimilars Price (US$/Unit) by Type (2020-2031)
Figure 56. Global Sales Market Share of Osteoporosis Biosimilars by Application (2020-2031)
Figure 57. Global Revenue Market Share of Osteoporosis Biosimilars by Application (2020-2031)
Figure 58. Global Osteoporosis Biosimilars Price (US$/Unit) by Application (2020-2031)
Figure 59. Osteoporosis Biosimilars Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
